1) (社) 日本透析医学会統計調査委員会. 図説わが国の慢性透析療法の現況 2008年12月31日現在. http://www.jsdt.or.jp/overview_confirm.html
2) Retnakaran R, Cull CA, Thorne KI, Adler AI, Holman RR ; UKPDS Study Group. Risk factors for renal dysfunction in type 2 diabetes : U.K. Prospective Diabetes Study 74. Diabetes 2006 ; 55 : 1832-9.
3) Adler AI, Stevens RJ, Manley SE, Bilous RW, Cull CA, Holman RR ; UKPDS GROUP. Development and progression of nephropathy in type 2 diabetes : the United Kingdom Prospective Diabetes Study (UKPDS 64). Kidney Int 2003 ; 63 : 225-32.
5) Ravid M, Brosh D, Levi Z, Bar-Dayan Y, Ravid D, Rachmani R. Use of enalapril to attenuate decline in renal function in normotensive, normoalbuminuric patients with type 2 diabetes mellitus. A randomized, controlled trial. Ann Intern Med 1998 ; 128 : 982-8.
6) Ruggenenti P, Fassi A, Ilieva AP, Bruno S, Iliev IP, Brusegan V, et al ; Bergamo Nephrologic Diabetes Complications Tria (l BENEDICT) Investigators. Preventing microalbuminuria in type 2 diabetes. N Engl J Med 2004 ; 351 : 1941-51.
7) Parving HH, Lehnert H, Bro chner-Mortensen J, Gomis R, Andersen S, Arner P ; Irbesartan in Patients with Type 2 Diabetes and Microalbuminuria Study Group. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 2001 ; 345 : 870-8.
8) Viberti G, Wheeldon NM ; MicroAlbuminuria Reduction With VALsartan (MARVAL) Study Investigators. Microalbuminuria reduction with valsartan in patients with type 2 diabetes mellitus : a blood pressure-independent effect. Circulation 2002 ; 106 : 672-8.
9) Makino H, Haneda M, Babazono T, Moriya T, Ito S, Iwamoto Y, et al ; INNOVATION Study Group. Prevention of transition from incipient to overt nephropathy with telmisartan in patients with type 2 diabetes. Diabetes Care 2007 ; 30 : 1577-8.
10) Lewis EJ, Hunsicker LG, Clarke WR, Berl T, Pohl MA, Lewis JB, et al ; Collaborative Study Group. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001 ; 345 : 851-60.
11) Brenner BM, Cooper ME, de Zeeuw D, Keane WF, Mitch WE, Parving HH, et al ; RENAAL Study Investigators. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001 ; 345 : 861-9.
12) 赤井裕輝. 多角的強化療法による糖尿病腎症の進展抑制. Mebio 2006 ; 23 (7) : 94-100.